Themis Medicare Limited has pledged 3,50,000 equity shares of Gujarat Themis Biosyn Limited to Jio Credit Limited on January 12, 2026, as part of a strategic financing arrangement. The disclosure was made under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Share Pledge Details

The pledge transaction involves key financial parameters that reflect Themis Medicare's shareholding structure in Gujarat Themis Biosyn:

Shareholding Position

Themis Medicare Limited maintains a significant stake in Gujarat Themis Biosyn, with the recent pledge affecting its encumbered shareholding position:

Purpose and Strategic Rationale

The share pledge serves a specific financial objective for Themis Medicare Limited. The company has entered into a facility cum pledge agreement with Jio Credit Limited to access borrowing facilities worth ₹10.00 crores. The primary purpose of this arrangement is to facilitate the repayment of existing high-interest-bearing loans, thereby reducing the overall finance cost burden on the company.

Regulatory Compliance

The disclosure was filed on January 14, 2026, in compliance with SEBI regulations governing substantial acquisition of shares and takeovers. Gujarat Themis Biosyn Limited's shares are listed on both BSE Limited and National Stock Exchange of India Limited, making the regulatory disclosure mandatory for such encumbrance transactions.

The pledge represents a routine corporate financing activity where promoter companies utilize their shareholdings as collateral to access favorable borrowing terms and optimize their capital structure.

Gujarat Themis Biosyn Limited (GTBL) has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director, while continuing to demonstrate strong financial performance in its recent quarterly results.

Postal Ballot for Director Appointment

GTBL has issued a postal ballot notice to shareholders for the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director. The key details of the postal ballot are:

The company has engaged Central Depository Services (India) Limited (CDSL) to provide remote e-voting facility for the postal ballot process.

Director Profile and Remuneration

Mr. Rajneesh Anand brings extensive experience to the board:

• Mechanical Engineering graduate from M.S. University, Baroda
• Postgraduate in Management from Jamnalal Bajaj Institute, Mumbai
• Associated with Themis Group since 1977 (over four decades)
• Currently serves as Director of Themis Medicare Limited
• Holds 1,69,770 shares in the company

The proposed remuneration of ₹10.00 lakhs per month will be paid as professional fees under Section 197(4) of the Companies Act, 2013, for strategic advisory and supervisory services.

Financial Performance Highlights

The company's Q2 financial results demonstrate robust growth across key metrics:

GTBL's performance shows strong improvement in both revenue growth and profitability margins.

Operational Expansion

GTBL has successfully completed a major expansion of its manufacturing capabilities:

This expansion significantly strengthens GTBL's fermentation capabilities and positions the company to meet growing demand for pharmaceutical ingredients.

Strategic Outlook

With the proposed appointment of an experienced industry veteran and the successful expansion of manufacturing capacity, Gujarat Themis Biosyn appears well-positioned for continued growth in the bulk drugs manufacturing sector. The company's focus on enhancing production capabilities and strengthening board expertise aligns with its strategic objectives in the pharmaceutical industry.